Loading news...
DURHAM, N.C., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it will release its fourth quarter and full year 2025 financial results before the market opens on Thursday, February 26, 2026.
Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Fortrea Holdings Inc. (FTRE) and Acadia Pharmaceuticals (ACAD). But which of these two stocks is more attractive to value investors?
NEW YORK and NEW ORLEANS, Jan. 20, 2026 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Fortrea Holdings Inc. (FTRE) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Fortrea Holdings Inc. (FTRE) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Fortrea (NASDAQ: FTRE - Get Free Report) and Avalon GloboCare (NASDAQ: ALBT - Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Earnings and Valuation This table compares Fortrea and
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Fortrea Holdings Inc. (FTRE) or Acadia Pharmaceuticals (ACAD). But which of these two companies is the best option for those looking for undervalued stocks?
DURHAM, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced an updated presentation time of 11:15 am PST on Tuesday, January 13, 2026, at the J.P. Morgan Annual Healthcare Conference (San Francisco).
Fortrea Holdings Inc. (FTRE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
DURHAM, N.C., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that CEO Anshul Thakral, CFO Jill McConnell, and SVP of Investor Relations, Tracy Krumme will participate in the following conference in January: J.P.
PHILADELPHIA, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Alexandria Real Estate Equities, Inc. (NYSE: ARE): Grabar Law Office is investigating claims on behalf of shareholders of Alexandria Real Estate Equities, Inc. (NYSE: ARE). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
DURHAM, N.C., Dec. 10, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization, today announced the granting of an inducement award of restricted stock units (“RSUs”) on December 10, 2025, to two newly hired employees.
PRAGUE, Czech Republic and DURHAM, N.C., Dec. 04, 2025 (GLOBE NEWSWIRE) -- SCTbio, a leading European CDMO specializing in GMP manufacturing for cell-based products, and Fortrea, a leading global contract research organization (CRO), today announced a strategic collaboration agreement between the two companies.
Capital Fund Management S.A. boosted its holdings in shares of Fortrea Holdings Inc. (NASDAQ: FTRE) by 189.8% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 451,074 shares of the company's stock after purchasing an additional 295,421 shares during the quarter. Capital Fund
Fortrea Holdings Inc. (FTRE) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
DURHAM, N.C., Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that chief executive officer, Anshul Thakral, chief financial officer, Jill McConnell, and senior vice president of investor relations, Tracy Krumme, will participate in the following conferences in December:
DURHAM, N.C., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced that it has completed its debt tender offer (the “Tender Offer”) described in the Offer to Purchase dated October 20, 2025 by purchasing $75,743,000 in aggregate of the Company's outstanding 7.500% Senior Secured Notes due 2030 (CUSIP No. 34965K AA5 (Rule 144A); U31685 AA5 (Reg S)) (each, a “Note” and collectively, the “Notes”). The Tender Offer to repurchase of a portion of the Notes satisfied a requirement relating to the Company's divestiture of its Fortrea Patient Access and Endpoint Clinical businesses completed in June 2024. Fortrea's purchase of the tendered Notes on November 21, 2025, reduced the principal outstanding on the Notes from $570,000,000 to $494,257,000.
DURHAM, N.C., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (CRO), today announced the appointment of Agnieszka (Aggie) M.
PHILADELPHIA, Nov. 15, 2025 (GLOBE NEWSWIRE) -- Avantor, Inc. (NYSE: AVTR): Grabar Law Office is investigating claims on behalf of shareholders of Avantor, Inc. (NYSE: AVTR). The investigation concerns whether certain officers and directors breached their fiduciary duties.
DURHAM, N.C., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Velocity Clinical Research (Velocity), the leading fully integrated site organization, today announces the appointment of Andrew (Drew) Reina as Chief Revenue Officer (CRO), effective immediately.